DE60111205D1 - Triarylimidazol-derivate als cytokin-inhibitoren - Google Patents

Triarylimidazol-derivate als cytokin-inhibitoren

Info

Publication number
DE60111205D1
DE60111205D1 DE60111205T DE60111205T DE60111205D1 DE 60111205 D1 DE60111205 D1 DE 60111205D1 DE 60111205 T DE60111205 T DE 60111205T DE 60111205 T DE60111205 T DE 60111205T DE 60111205 D1 DE60111205 D1 DE 60111205D1
Authority
DE
Germany
Prior art keywords
sub
cytokin
inhibitors
triarylimidazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60111205T
Other languages
English (en)
Inventor
John David Harling
Mary Gaster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE60111205D1 publication Critical patent/DE60111205D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
DE60111205T 2000-03-27 2001-03-26 Triarylimidazol-derivate als cytokin-inhibitoren Expired - Lifetime DE60111205D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007405.4A GB0007405D0 (en) 2000-03-27 2000-03-27 Compounds
PCT/GB2001/001314 WO2001072737A1 (en) 2000-03-27 2001-03-26 Triarylimidazole derivatives as cytokine inhibitors

Publications (1)

Publication Number Publication Date
DE60111205D1 true DE60111205D1 (de) 2005-07-07

Family

ID=9888509

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60111205T Expired - Lifetime DE60111205D1 (de) 2000-03-27 2001-03-26 Triarylimidazol-derivate als cytokin-inhibitoren

Country Status (9)

Country Link
US (1) US6906089B2 (de)
EP (1) EP1268465B1 (de)
JP (1) JP2003528870A (de)
AT (1) ATE296821T1 (de)
AU (1) AU4257901A (de)
CO (1) CO5280078A1 (de)
DE (1) DE60111205D1 (de)
GB (1) GB0007405D0 (de)
WO (1) WO2001072737A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225730A1 (en) * 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
EP1355903B1 (de) * 2001-02-02 2005-03-16 SmithKline Beecham Corporation Pyrazolderivate gegen tgf überexprimierung
PL364230A1 (en) 2001-03-12 2004-12-13 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
AU2002339268B2 (en) 2001-05-24 2007-05-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
GB0127430D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
AU2003260345A1 (en) * 2002-07-31 2004-02-23 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
AU2003256297A1 (en) 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
EP1542994B1 (de) 2002-09-18 2009-04-29 Pfizer Products Inc. Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf)
WO2004026307A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
OA12925A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
AP2005003264A0 (en) * 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
CA2496295C (en) 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
JP2006217801A (ja) * 2003-01-15 2006-08-24 Kirin Brewery Co Ltd ＴＧＦβ阻害活性を有する化合物の新規用途
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1613310A1 (de) * 2003-04-10 2006-01-11 Avanir Pharmaceuticals Imidazol-derivative zur behandlung von allergischen und hyperproliferativen erkrankungen
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US7678810B2 (en) 2004-03-05 2010-03-16 Taisho Pharmaceutical Co., Ltd Thiazole derivative
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20080319012A1 (en) 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
EP1771171A1 (de) * 2004-07-29 2007-04-11 Schering-Plough Ltd. Verwendung von alk-5-hemmern zur modulation bzw. hemmung der myostatinaktivität zur verstärkung von magergewebe bei tieren
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
EP2152093A4 (de) * 2007-05-04 2011-05-25 Jana Pickova Verbundfutter für aquakulturen
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
ES2617957T3 (es) 2007-08-03 2017-06-20 Summit (Oxford) Limited Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
UA108979C2 (uk) * 2008-03-14 2015-07-10 Оцука Фармасьютікал Ко., Лтд. Застосування тетоміласту при лікуванні фіброзу або легеневої емфіземи
CA2718936A1 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
EP2476672A1 (de) 2010-12-22 2012-07-18 Momentive Specialty Chemicals Research Belgium S.A. Glycidylester von alpha,alpha-verzweigten Säurezusammensetzungen
PT2731949T (pt) 2011-07-13 2018-06-15 Tiumbio Co Ltd Imidazóis substituídos com 2-piridilo como inibidores de alk5 e/ou alk4
EP2855665B8 (de) 2012-05-30 2019-09-25 Cornell University Erzeugung von funktionellen und beständigen endothelzellen aus zellen aus menschlicher amniotischer flüssigkeit
RS60318B1 (sr) 2012-08-01 2020-07-31 Ikaika Therapeutics Llc Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela
CA2901747A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP3888640A1 (de) 2013-06-05 2021-10-06 AgeX Therapeutics, Inc. Zusammensetzungen und verfahren zur induzierten geweberegeneration in säugerspezies
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
TW202039459A (zh) 2018-12-11 2020-11-01 美商施萬生物製藥研發 Ip有限責任公司 Alk5 抑制劑
EP3897689A1 (de) 2018-12-21 2021-10-27 Northwestern University Verwendung von annexinen zur vorbeugung und behandlung von muskelmembranverletzungen
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
IL293084A (en) 2019-11-22 2022-07-01 Theravance Biopharma R& D Ip Llc 5,1-Converted naphthyridines or quinolines as alk5 inhibitors
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
CA3184990A1 (en) 2020-07-15 2022-01-20 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
EP4182322B1 (de) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido-oxazin-derivate als alk5-inhibitoren
AU2021307560A1 (en) 2020-07-15 2023-02-23 Chiesi Farmaceutici S.P.A. Pyrido oxazine amino derivatives as ALK5 inhibitors
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
AU2022351219A1 (en) 2021-09-21 2024-05-02 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH561716A5 (de) 1971-05-10 1975-05-15 Ciba Geigy Ag
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
CA2271963A1 (en) * 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5955480A (en) * 1996-11-20 1999-09-21 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
JPH11180958A (ja) 1997-12-24 1999-07-06 Yamanouchi Pharmaceut Co Ltd 新規アミン誘導体
ES2187473T3 (es) * 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.

Also Published As

Publication number Publication date
US20030149277A1 (en) 2003-08-07
ATE296821T1 (de) 2005-06-15
CO5280078A1 (es) 2003-05-30
AU4257901A (en) 2001-10-08
EP1268465B1 (de) 2005-06-01
EP1268465A1 (de) 2003-01-02
JP2003528870A (ja) 2003-09-30
WO2001072737A1 (en) 2001-10-04
GB0007405D0 (en) 2000-05-17
US6906089B2 (en) 2005-06-14

Similar Documents

Publication Publication Date Title
DE60111205D1 (de) Triarylimidazol-derivate als cytokin-inhibitoren
ATE231143T1 (de) Triarylimidazole
DK1161428T3 (da) Pyrimidinforbindelser
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
EP1340755A4 (de) Mittel mit wirkung gegen helicobacter
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE259813T1 (de) Triazolopyrimidinderivate
WO2003031414A1 (fr) Nouveau compose heterocyclique et agent anti-inflammatoire
MA27143A1 (fr) Utilisation de derives de 2-amino-4- pyridylmethyl-thiazoline comme inhibiteurs de no-synthase inductible
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
DE69619259T2 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
RS50033B (sr) Derivati etansulfonil-piperidina
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
ATE388710T1 (de) Phthalazinderivate als phosphodiesterase-4-hemmer
DK0651747T3 (da) Carbostyrilderivater

Legal Events

Date Code Title Description
8332 No legal effect for de